Coherus Oncology, Inc. Debt Instrument, Repurchase Amount
Coherus Oncology, Inc. (CHRS) had Debt Instrument, Repurchase Amount of $59.90 million as of 2025-05-15, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Debt Instruments
us-gaap:DebtInstrumentRepurchaseAmount · last filed 2026-03-09
- 2025-05-15: Debt Instrument, Repurchase Amount $59.90M.
| Period end | Debt Instrument, Repurchase Amount |
|---|---|
| 2025-05-15 | $59.90M 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |